Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021
ACCESSWIRE
14 May 2021, 04:05 GMT+10
HILLSIDE, NJ / ACCESSWIRE / May 13, 2021 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the 'Company' or 'INBP') reports its financial results for the quarter ended March 31, 2021.
Revenue for the quarter ended March 31, 2021 was $17.1 million compared to $13.6 million for the quarter ended March 31, 2020, an increase of $3.4 million or 25.2%. The Company had operating income of $1.7 million and $1.0 million in the quarters ended March 31, 2021 and 2020, respectively.
Revenues for the nine-month period ended March 31, 2021 were $46.5 million compared to $39.2 million for the nine-month period ended March 31, 2020, an increase of $7.3 million or 18.6%. The Company had operating income for the nine-month period ended March 31, 2021 of $4.5 million compared to operating income of $2.6 million for the nine-month period ended March 31, 2020.

Related Keywords

Dina Masi ,Christina Kay ,Riva Sheppard ,Biopharma Inc ,Officers Of The Company ,Integrated Biopharma ,Contract Manufacturing Segment ,Co Chief Executive Officers ,Private Securities Litigation Reform Act ,Risk Factor ,Annual Report ,Quarterly Reports ,United States Wire Group ,தினா மாசி ,கிறிஸ்டினா காய் ,ரீவ ஷெப்பர்ட் ,அதிகாரிகள் ஆஃப் தி நிறுவனம் ,ஒப்பந்த உற்பத்தி பிரிவு ,இணை தலைமை நிர்வாகி அதிகாரிகள் ,ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,ஆபத்து காரணி ,ஆண்டு அறிக்கை ,காலாண்டு அறிக்கைகள் ,ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு ,